| Nome |
# |
|
Metastatic renal cell carcinoma management: from molecular mechanism to clinical practice, file e383532d-7afe-15e8-e053-a505fe0a3de9
|
181
|
|
Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC), file e3835312-332b-15e8-e053-a505fe0a3de9
|
143
|
|
Immunotherapy in HER2-positive breast cancer. state of the art and future perspectives, file e3835326-cb79-15e8-e053-a505fe0a3de9
|
115
|
|
Immune effects of CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: relief from immunosuppression is associated with clinical response, file e383532e-6f7a-15e8-e053-a505fe0a3de9
|
115
|
|
Acrocyanosis, digital ischemia and acronecrosis as first manifestations of endometrial adenocarcinoma: case presentation and literature review, file e3835318-cbb2-15e8-e053-a505fe0a3de9
|
110
|
|
223Ra-dichloride therapy in an elderly bone metastatic castration-resistant prostate cancer patient: a case report presentation and comparison with existing literature, file e383531b-e6de-15e8-e053-a505fe0a3de9
|
110
|
|
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study, file e3835321-b842-15e8-e053-a505fe0a3de9
|
110
|
|
Triple negative breast cancer: new perspectives for targeted therapies, file e3835311-d524-15e8-e053-a505fe0a3de9
|
108
|
|
Progesterone therapy in endometrial cancer, file e3835318-be6f-15e8-e053-a505fe0a3de9
|
108
|
|
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study, file e3835323-5c9a-15e8-e053-a505fe0a3de9
|
107
|
|
Multimodal treatment for local recurrent malignant gliomas: resurgery and/or reirradiation followed by chemotherapy, file e383531d-cfbd-15e8-e053-a505fe0a3de9
|
102
|
|
Therapeutic approach in glioblastoma multiforme with primitive neuroectodermal tumor components: case report and review of the literature, file e3835323-6a13-15e8-e053-a505fe0a3de9
|
102
|
|
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: the EverExt study, file e3835323-6a17-15e8-e053-a505fe0a3de9
|
101
|
|
Association between diverticulosis and colonic neoplastic lesions in individuals with a positive faecal immunochemical test, file e3835323-5603-15e8-e053-a505fe0a3de9
|
100
|
|
Pembrolizumab in programmed death ligand 1-positive endometrial cancer, file e3835318-a20d-15e8-e053-a505fe0a3de9
|
99
|
|
RE: Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition, file e3835322-d442-15e8-e053-a505fe0a3de9
|
97
|
|
Niraparib in ovarian cancer. results to date and clinical potential, file e3835317-a6f5-15e8-e053-a505fe0a3de9
|
95
|
|
Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting, file e3835323-1887-15e8-e053-a505fe0a3de9
|
95
|
|
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment, file e3835315-bd1f-15e8-e053-a505fe0a3de9
|
93
|
|
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab, file e3835323-37d4-15e8-e053-a505fe0a3de9
|
90
|
|
M8Concomitant versus sequential Fotemustine and Bevacizumab in recurrent malignant gliomas: treatment response and survival outcomes in a retrospective analysis, file e3835328-a1d3-15e8-e053-a505fe0a3de9
|
89
|
|
Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens, file e3835325-68f5-15e8-e053-a505fe0a3de9
|
88
|
|
Early clear cell “sugar” lung cancer management: a case report and a brief literature review, file e3835323-f325-15e8-e053-a505fe0a3de9
|
84
|
|
Role of chemotherapy in vulvar cancers: time to rethink standard of care?, file e383532d-39c4-15e8-e053-a505fe0a3de9
|
83
|
|
Innovations in the treatment of ovarian cancer. Analysis of the therapeutic development: from platinum to immunotherapy [Innovazioni terapeutiche nel trattamento del tumore ovarico. Analisi del percorso per lo sviluppo terapeutico: dal platino all’immunoterapia], file e3835323-6c60-15e8-e053-a505fe0a3de9
|
80
|
|
Breast metastasis and lung large-cell neuroendocrine carcinoma: first clinical observation, file e3835323-58fc-15e8-e053-a505fe0a3de9
|
78
|
|
"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome, file e3835321-f215-15e8-e053-a505fe0a3de9
|
74
|
|
Adjuvant therapy for early uterine high-grade leiomyosarcoma, file e3835322-ddf2-15e8-e053-a505fe0a3de9
|
68
|
|
S47A retrospective analysis to evaluted the off-label use Bevacizumab in recurrent malignant gliomas, file e3835328-94ad-15e8-e053-a505fe0a3de9
|
67
|
|
Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era, file e383532c-6c80-15e8-e053-a505fe0a3de9
|
63
|
|
Circulating tumor cells in right-and left-sided colorectal cancer, file e3835328-91b7-15e8-e053-a505fe0a3de9
|
62
|
|
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting, file e3835322-d440-15e8-e053-a505fe0a3de9
|
59
|
|
Breast cancer risk after ovarian stimulation for In vitro fertilization, file e3835315-d417-15e8-e053-a505fe0a3de9
|
57
|
|
Neoadjuvant immune-checkpoint blockade in triple-negative breast cancer: current evidence and literature-based meta-analysis of randomized trials, file e383532b-35b3-15e8-e053-a505fe0a3de9
|
57
|
|
Fertility preservation and reproductive health in patients undergoing hematopoietic stem cell transplantation, file e3835326-cb67-15e8-e053-a505fe0a3de9
|
53
|
|
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study, file e383532a-cd31-15e8-e053-a505fe0a3de9
|
48
|
|
Radium‑223 in patients with metastatic castration‑resistant prostate cancer: efficacy and safety in clinical practice, file e383531e-b119-15e8-e053-a505fe0a3de9
|
46
|
|
In vivo imaging-based techniques for early diagnosis of oral potentially malignant disorders—systematic review and meta-analysis, file e383532d-5841-15e8-e053-a505fe0a3de9
|
46
|
|
INfluenza vaccine indication during therapy with Immune checkpoint inhibitors: a transversal challenge. the INVIDIa study, file e3835323-170e-15e8-e053-a505fe0a3de9
|
43
|
|
COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience, file 45f6d0d2-c79f-4c8b-a254-29e4d8fe77a0
|
33
|
|
The potential role of genomic signature in stage II relapsed colorectal cancer (CRC) patients: a mono-institutional study, file e383532f-3489-15e8-e053-a505fe0a3de9
|
32
|
|
Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis, file e3835311-d606-15e8-e053-a505fe0a3de9
|
31
|
|
The value of the multidisciplinary team in metastatic renal cell carcinoma: paving the way for precision medicine in toxicities management, file 70cc720a-cf13-49cc-8fd3-26a3e680d83f
|
26
|
|
Angioside: the role of angiogenesis and hypoxia in lung neuroendocrine tumours according to primary tumour location in left or right parenchyma, file d506fb72-790f-4f1a-b839-ee5056f6ab87
|
25
|
|
The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy, file e01ed9e7-9e05-4156-bfb5-bb589f98bd58
|
20
|
|
Angiogenic factors as prognostic markers in neuroendocrine neoplasms, file e383532e-2fa1-15e8-e053-a505fe0a3de9
|
20
|
|
A 17-gene expression signature for early identification of poor prognosis in clear cell renal cell carcinoma, file e383532f-136c-15e8-e053-a505fe0a3de9
|
17
|
|
Toxicity of targeted therapy in non-small-cell lung cancer management, file e3835311-63f8-15e8-e053-a505fe0a3de9
|
16
|
|
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting, file e383532e-fa2b-15e8-e053-a505fe0a3de9
|
15
|
|
Circulating tumor cells in high-risk nonmetastatic colorectal cancer, file e3835312-2d6b-15e8-e053-a505fe0a3de9
|
13
|
|
Circulating hpv dna in the management of oropharyngeal and cervical cancers: current knowledge and future perspectives, file 28d040f3-75f0-4669-9847-0444212b96d4
|
12
|
|
Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach, file 0bedcce7-5b61-45ee-b557-7de4e188289d
|
11
|
|
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial, file 414ca0a4-8e30-4a18-94ef-25ad85b00f14
|
11
|
|
Synchronous primary neoplasms of the bladder, skin and breast in a male patient: A case report, file e3835311-cedf-15e8-e053-a505fe0a3de9
|
11
|
|
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: a real-world experience, file e3835321-b0d8-15e8-e053-a505fe0a3de9
|
11
|
|
MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study, file a4d4c711-927f-4aaf-9908-49639ba20321
|
10
|
|
Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families, file e3835311-cab1-15e8-e053-a505fe0a3de9
|
10
|
|
Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients, file e3835311-ae07-15e8-e053-a505fe0a3de9
|
9
|
|
Efficacy, safety, and cost-effectiveness (CE) analysis of pegfilgrastim (P) and lenograstim (L) in patients (pts) with nonmetastatic breast cancer (nmBC) receiving myelosuppressive chemotherapy (mCT)., file e3835316-0981-15e8-e053-a505fe0a3de9
|
9
|
|
null, file e5e1a280-5390-4e9c-a00f-60b5a538c9cc
|
9
|
|
Treatment of low-grade gastric MALT-lymphoma unresponsive to Helicobacter pylori therapy : A pooled-data analysis, file e3835311-aa3e-15e8-e053-a505fe0a3de9
|
8
|
|
Plerixafor and autologous stem cell transplantation: Impressive result in a chemoresistant testicular cancer patient treated with high-dose chemotherapy, file e3835311-d0d0-15e8-e053-a505fe0a3de9
|
8
|
|
Gonadotropin-releasing hormone agonists for the preservation of ovarian function during chemotherapy., file e3835312-3f4f-15e8-e053-a505fe0a3de9
|
8
|
|
Incidence of chemotherapy (CT) induced amenorrhea in premenopausal patients (pts) with breast cancer (BC) following adjuvant anthracycline (A), cyclophosphamide (C), and taxane (T), file e3835315-d3cc-15e8-e053-a505fe0a3de9
|
8
|
|
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting, file e383532a-6618-15e8-e053-a505fe0a3de9
|
8
|
|
Capecitabine and Temozolomide (CAPTEM) in advanced neuroendocrine neoplasms (NENs): a systematic review and pooled analysis, file c4aec32f-d524-44ae-a154-11c0021ab0ae
|
7
|
|
Diverticulosis and Colorectal Cancer between Lights and Shadows, file e3835311-6378-15e8-e053-a505fe0a3de9
|
7
|
|
Troponin-T and myoglobin plus echocardiographic evaluation for monitoring early cardiotoxicity of weekly epirubicin-paclitaxel in metastatic breast cancer patients., file e3835311-637a-15e8-e053-a505fe0a3de9
|
7
|
|
BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models, file e3835311-b082-15e8-e053-a505fe0a3de9
|
7
|
|
Malignant transformation of well-differentiated papillary mesothelioma 13 years after the diagnosis: a case report, file e3835311-d60f-15e8-e053-a505fe0a3de9
|
7
|
|
17) Follow-up of intestinal metaplasia in the stomach: When, how and why., file e3835311-d621-15e8-e053-a505fe0a3de9
|
7
|
|
Continuous, low-dose capecitabine for patients with recurrent colorectal cancer, file e3835313-f830-15e8-e053-a505fe0a3de9
|
7
|
|
RE: Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition, file e383532b-1777-15e8-e053-a505fe0a3de9
|
7
|
|
The impact of the Hippo pathway and cell metabolism on pathological complete response in locally advanced Her2+ breast cancer: the TRISKELE multicenter prospective study, file b8d468f2-b4a8-4d52-9113-ee7da975a0d1
|
6
|
|
Role of vacuum assisted biopsy(mammotome) in early detection of breast cancer, file e3835312-55d5-15e8-e053-a505fe0a3de9
|
6
|
|
Subcutaneous metastases from colon cancer: A case report, file e3835313-9589-15e8-e053-a505fe0a3de9
|
6
|
|
G-CSF related bone pain (BP) and Bv8/PK2 expression: Is there a link in breast cancer (BC) patients (pts) treated with FEC100 adjuvant chemotherapy (CT)?, file e3835316-32ef-15e8-e053-a505fe0a3de9
|
6
|
|
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence, file e3835324-d18f-15e8-e053-a505fe0a3de9
|
6
|
|
Network analysis to determine association between immuno-related toxicities and immune soluble profile in patients treated with anti-PD-1, file 30d0ac26-b94f-4eec-a7e4-2299033d0974
|
5
|
|
Combined surgery and radiotherapy as curative treatment for tracheal adenoid cystic carcinoma: a case report, file dd1b577a-b48e-48e1-b934-2c74f192b0c3
|
5
|
|
DETERMINATION OF PAH-DNA ADDUCTS IN LUNG TISSUE OF CANCER PATIENTS, file e3835311-a573-15e8-e053-a505fe0a3de9
|
5
|
|
Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families, file e3835311-f500-15e8-e053-a505fe0a3de9
|
5
|
|
Exosomes factory: a new strategy for antitumour vaccines, file e3835312-3645-15e8-e053-a505fe0a3de9
|
5
|
|
Expression of er, pgr, her-2, and ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, file e3835325-af8c-15e8-e053-a505fe0a3de9
|
5
|
|
The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targets, file 89d4a61c-622b-4fbd-8010-08e62f36e607
|
4
|
|
Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives, file a2ffb1cb-4a5c-4324-8874-5939bf90a4a8
|
4
|
|
Emerging Role of Cetuximab in the Treatment of Colorectal Cancer, file e3835311-d623-15e8-e053-a505fe0a3de9
|
4
|
|
Cerebral metastases in patients with left atrial myxoma, file e3835315-a6f7-15e8-e053-a505fe0a3de9
|
4
|
|
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience, file e383531d-6cf8-15e8-e053-a505fe0a3de9
|
4
|
|
The 5-Ws of immunotherapy in head and neck cancer, file e3835327-6450-15e8-e053-a505fe0a3de9
|
4
|
|
Alteration of E-cadherin expression in gastric mucosa: role of intestinal metaplasia and Helicobacter pylori infection., file e3835311-8177-15e8-e053-a505fe0a3de9
|
3
|
|
Relationship between b-catenin expression and epithelial cell proliferation in gastric mucosa with intestinal metaplasia., file e3835311-a5b8-15e8-e053-a505fe0a3de9
|
3
|
|
Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff?, file e3835311-d6e8-15e8-e053-a505fe0a3de9
|
3
|
|
Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer, file e3835311-f270-15e8-e053-a505fe0a3de9
|
3
|
|
Improvement in Progression-Free Survival in OCEANS Bevacizumab Arm: A Critical Point of View, file e3835311-fa2e-15e8-e053-a505fe0a3de9
|
3
|
|
Chemotherapy and Target Therapy in the Management of Adult High-Grade Gliomas, file e3835312-0bf9-15e8-e053-a505fe0a3de9
|
3
|
|
null, file e3835315-83d6-15e8-e053-a505fe0a3de9
|
3
|
|
Quality of life effects of ovarian suppression in the suppression of ovarian function trial, file e3835315-bbbe-15e8-e053-a505fe0a3de9
|
3
|
|
Primary endocrine therapy in older women with locally advanced breast cancer, file e3835316-097a-15e8-e053-a505fe0a3de9
|
3
|
|
Intraperitoneal chemotherapy in advanced ovarian cancer: old and novel questions, file e3835326-cd12-15e8-e053-a505fe0a3de9
|
3
|
| Totale |
3.987 |